- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02672644
Non-comparative Evaluation of Facial Expressions Following Lower Face Correction Using Emervel Classic and Emervel Deep
A Single-Center, Non-Comparative Study to Evaluate Subject Recovery Following Correction of Bilateral Nasolabial Folds Using Emervel® Classic Lidocaine and Emervel® Deep Lidocaine
Study is designed to characterize subject and treating investigator reported outcomes in the early post-treatment period, following bilateral correction of nasolabial folds using Emervel Classic and Emervel Deep.
- to evaluate subject-reported return to social engagement, after the initial treatment (Baseline/Day 1 visit).
- to evaluate change in Global Aesthetic Improvement Scale (GAIS) at day 30- subject/investigator reported
- to evaluate subject satisfaction with treatment outcome at baseline, day 14 and day 30.
- to evaluate change in Wrinkle Severity Rating Scale (WSRS) from baseline to post-treatment follow-up time points at day 14 and Day 30 - investigator reported
- to evaluate all adverse events during the course of the study
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Quebec
-
Montreal, Quebec, Canada, H3Z 1B7
- Arthur Swift Research Inc.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Key Inclusion Criteria:
- Male or female subjects, 35 to 60 years of age
- Bilateral NLFs: severe (WSRS = 4/4) or moderate (WSRS = 3/3), as assessed by the treating investigator
- Subjects of childbearing potential who agree to use medically accepted methods of contraception during the study and for 30 days following study completion.
Childbearing potential is defined as not being surgically sterile (e.g., hysterectomy, bilateral salpingo-oophorectomy, or tubal ligation) or those who are not post-menopausal (absence of menstruation for at least 1 year prior to Day 1).
- If not surgically sterile or post-menopausal, the subject agrees to use acceptable forms of contraception. Acceptable methods of contraception are defined as follows:
- use of oral/systemic contraceptives for at least 3 months prior to the start of the study; or
- use of an intrauterine device; or
- use of double barrier (e.g., condom or diaphragm and spermicidal foam/gel, condom and diaphragm); or
- use of contraceptive implants or injectables for at least 28 days prior to the start of the study; or
- partner with vasectomy at least 3 months prior to study start; or
- strict abstinence.
Females of child bearing potential must have negative urine pregnancy test (UPT) at Day 1 and Day 14 if touch-up is to be performed.
Key Exclusion Criteria:
- Subject who presents with a severity of wrinkles or folds that require other treatments, e.g. laser treatment, chemical peeling, to achieve optimal correction
- Previous facial surgery, including aesthetic facial surgical therapy, liposuction or tattoo, in the treatment area
- Previous tissue augmenting therapy or contouring with permanent filler-type injectable product
- Previous tissue augmenting therapy with non-permanent filler or fat-injection in the facial area to be treated, within twelve (12) months before treatment
- Previous tissue revitalisation treatment with neurotoxin below the zygomatic arch, within six (6) months before treatment
- Previous tissue revitalisation treatment with laser or light, mesotherapy, chemical peeling or dermabrasion below the zygomatic arch within six (6) months before treatment
- Subject who presents with severe midface volume loss
- Subject has a beard or facial hair that, in the investigator's opinion, would interfere with the study injections and/or study assessments
- Woman who plans to become pregnant during the study
- Woman who is pregnant or breast feeding
- Known/previous allergy or hypersensitivity to any injectable hyaluronic acid (HA) gel
- Known/previous allergy or hypersensitivity to local anaesthetics, e.g. lidocaine or other amide-type anaesthetics
- Known/previous allergy or hypersensitivity to gram-positive bacterial proteins
- History of severe or multiple allergies manifested by anaphylaxis
- History of bleeding disorders or treatment with anticoagulants or inhibitors of platelet aggregation within two (2) weeks before treatment
- Treatment with chemotherapy, immunosuppressive agents, immunomodulatory therapy (e.g. monoclonal antibodies), systemic or topical (facial) corticosteroids (inhaled corticoids are allowed) within three (3) months before study treatment
- Any medical condition or treatment that, in the opinion of the treating investigator, would make the subject unsuitable for inclusion
- Study site personnel, close relatives of the study site personnel (e.g. parents, children, siblings, or spouse), employees, or close relatives of employees at the Sponsor company
- Participation in any clinical study within thirty (30) days before treatment
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Emervel Classic
Subjects treated with Emervel Classic (moderate NLFs; WSRS = 3/3).
Subjects receiving bilateral treatment of NLFs following approved product labeling.
|
Subjects requiring bilateral correction of NLFs and meeting eligibility criteria will be enrolled and treated with Emervel Classic (moderate NLFs; WSRS = 3/3)
|
Experimental: Emervel Deep
Subjects treated with Emervel Deep (severe NLFs; WSRS = 4/4).
Subjects receiving bilateral treatment of NLFs following approved product labeling.
|
Subjects requiring bilateral correction of NLFs and meeting eligibility criteria will be enrolled and treated with Emervel Deep (severe NLFs; WSRS = 4/4).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Subject-reported time of return to social engagement after initial treatment
Time Frame: 30 days
|
Time of return to social engagement (in hours)
|
30 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from baseline to post-treatment follow-up time points in subject reported GAIS
Time Frame: up to 30 days
|
Change from baseline to post-treatment follow-up time points in the subject reported GAIS (photographs) at day 30
|
up to 30 days
|
Subject satisfaction with treatment outcome of the nasolabial folds
Time Frame: 30 days
|
Subject satisfaction with treatment assessments at baseline, day 14, and day 30
|
30 days
|
Change from baseline to post-treatment follow-up time points in treating investigator reported WSRS
Time Frame: 30 days
|
Change from baseline to post-treatment follow-up time points in the treating investigator reported WSRS at day 14 and day 30
|
30 days
|
Change from baseline to post-treatment follow-up time points in treating investigator reported GAIS
Time Frame: 30 days
|
Change from baseline to post-treatment follow-up time points in the treating investigator reported GAIS (photographs) at day 30
|
30 days
|
Incidence rate of subjects with adverse events (AEs)
Time Frame: 30 days
|
30 days
|
|
Incidence rate of subjects with injection-related adverse events
Time Frame: 30 days
|
Injection-related adverse events recorded by the subject in study diary
|
30 days
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Author Swift, MD, Arthur Swift Research Inc
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- GLI.04.SPR.US10346
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Wrinkles
-
Ulthera, IncTerminatedPeri-oral Wrinkles | Peri-orbital WrinklesUnited States
-
Cynosure, Inc.CompletedPeri-oral Wrinkles | Peri-orbital WrinklesUnited States
-
Anika Therapeutics, Inc.Completed
-
Ivo Pitanguy InstituteAllerganCompleted
-
Home Skinovations Ltd.Completed
-
Pacira CryoTech, Inc., a wholly owned subsidiary...Completed
-
Galderma R&DCompletedCheek WrinklesUnited States
-
Ulthera, IncCompleted
-
Deka Medical, Inc.CompletedWrinkles | RhytidesUnited States
-
Merz North America, Inc.CompletedDécolleté WrinklesUnited States
Clinical Trials on Emervel Classic
-
Galderma R&DCompletedWrinkles | Nasolabial Folds | Marionette Lines
-
Galderma R&DCompletedWrinkles and Folds in Lower FaceGermany
-
Galderma R&DCompletedLocal Tolerability After Lip Filler InjectionsGermany
-
Tuba MadenCompletedMultiple Sclerosis | Postural Balance | Cervical Region Disorder Nos | Muscle Tonus | ProprioceptionTurkey
-
Brazilan Center for Studies in DermatologyCompletedInjuries to the Wrist and HandBrazil
-
University of Sao PauloCompletedLow Back Pain | Myofascial Pain Syndromes | LumbagoBrazil
-
Fernanda Yanez RegonesiAmerican Academy of Dental Sleep MedicineRecruitingObstructive Sleep Apnea | OSA | NocturiaUnited States
-
LG Life SciencesCompletedCorrection of Nasolabial FoldsChina
-
Nevsehir Haci Bektas Veli UniversityCompleted
-
Nantes University HospitalUnknownElderly Patients in Complex SituationsFrance